BeyondSpring begins enrolment in Phase Ib/II trial of plinabulin and nivolumab combination for NSCLC

US-based biopharmaceutical company BeyondSpring has enrolled the first patient in its Phase Ib/II trial of plinabulin combined with nivolumab to treat metastatic non-small-cell lung cancer (NSCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news